La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
CytomX Therapeutics Gestione
Gestione criteri di controllo 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Sean McCarthy
Amministratore delegato
US$2.6m
Compenso totale
| Percentuale dello stipendio del CEO | 25.0% |
| Mandato del CEO | 13yrs |
| Proprietà del CEO | 0.7% |
| Durata media del management | 3.3yrs |
| Durata media del Consiglio di amministrazione | 4.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Compensazione vs Mercato: La retribuzione totale di Sean ($USD 2.61M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).
Compensazione vs guadagni: La retribuzione di Sean è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sean McCarthy (57 yo)
13yrs
Mandato
US$2,611,138
Compensazione
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 13yrs | US$2.61m | 0.68% $ 651.8k | |
| Senior VP & Chief Scientific Officer | 1.6yrs | US$1.21m | 0.076% $ 73.1k | |
| Senior VP | 3.3yrs | US$1.05m | 0.068% $ 65.1k | |
| Chief Financial Officer | 1.9yrs | Nessun dato | 0.032% $ 31.2k | |
| Senior VP | 6.3yrs | US$1.21m | 0.083% $ 79.7k | |
| Senior VP & Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Intellectual Property | 5.5yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 1.1yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Quality & Product Manufacturing | 1.6yrs | Nessun dato | Nessun dato | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | Nessun dato |
3.3yrs
Durata media
55.5yo
Età media
Gestione esperta: Il team dirigenziale di CTMX è considerato esperto (durata media dell'incarico 3.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 13yrs | US$2.61m | 0.68% $ 651.8k | |
| Independent Director | 5.3yrs | US$75.12k | 0.0066% $ 6.3k | |
| Member of Scientific Advisory Board | 4.6yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 3.7yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 8.9yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | US$8.03m | Nessun dato | |
| Independent Director | 2.9yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.6yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.6yrs | Nessun dato | Nessun dato |
4.6yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CTMX sono considerati esperti (durata media dell'incarico 4.6 anni).